The boss of Britain’s second-biggest pharmaceutical group, GSK, has warned the UK is at a “tipping point” and risks falling short of government ambitions to become a life sciences superpower despite Rishi Sunak’s pledge to ramp up spending in research and development.
On Wednesday, Emma Walmsley called for improvements in three key areas, saying the UK needed to reverse the decline in clinical trials, speed up regulatory approval for new treatments and deploy the latest medicines more rapidly.
